Thomas J. Rutkoski

发表

Site-specific PEGylation endows a mammalian ribonuclease with antitumor activity

Ronald T. Raines, R. Raines, L. E. Strong, 2011, Cancer biology & therapy.

Human ribonuclease with a pendant poly(ethylene glycol) inhibits tumor growth in mice.

R. Raines, L. E. Strong, J. Kink, 2013, Translational oncology.

Antitumor activity of ribonuclease multimers created by site-specific covalent tethering.

R. Raines, L. E. Strong, Christine I. Schilling, 2010, Bioconjugate chemistry.

Effectiveness and limitations of local structural entropy optimization in the thermal stabilization of mesophilic and thermophilic adenylate kinases

R. Bannen, G. Phillips, E. Bae, 2014, Proteins.

Combined Computational and Experimental Approaches to Sequence-Based Design of Protein Thermal Stability

Julie C. Mitchell, R. Bannen, G. Phillips, 2011 .

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia

R. Larson, K. Bhalla, O. Rosen, 2016, Haematologica.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

L. Stewart, R. V. van Etten, T. Haack, 2011, Cancer cell.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.

Stacie L. Bulfer, O. Rosen, M. Heinrich, 2019, Cancer cell.

Tuning the pK(a) of fluorescein to optimize binding assays.

Ronald T. Raines, R. Raines, L. Lavis, 2007, Analytical chemistry.

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

L. Stewart, Michael D. Kaufman, D. Flynn, 2015, Molecular Cancer Therapeutics.

Increasing the potency of a cytotoxin with an arginine graft.

Ronald T. Raines, R. Raines, S. Fuchs, 2007, Protein engineering, design & selection : PEDS.

Formation, Distribution, and Elimination of Infliximab and Anti-Infliximab Immune Complexes in Cynomolgus Monkeys

C. Wagner, S. Rousselle, K. Geboes, 2005, Journal of Pharmacology and Experimental Therapeutics.

Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A.

Julie C. Mitchell, R. Raines, Erin L. Kurten, 2005, Journal of molecular biology.

Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.

R. Raines, Thomas J. Rutkoski, 2008, Current pharmaceutical biotechnology.

Structure, dynamics, and specificity of endoglucanase D from Clostridium cellulovorans.

Greg L. Hura, Kevin N Dyer, G. Phillips, 2013, Journal of molecular biology.

A Phase 1 Study of DCC-2036, a Novel Oral Inhibitor of BCR-ABL Kinase, in Patients with Philadelphia Chromosome Positive (Ph+) Leukemias Including Patients with T315I Mutation

M. Berger, H. Kantarjian, J. Cortes, 2011 .

Abstract 2690: DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models

M. Heinrich, Michael D. Kaufman, D. Flynn, 2015 .